[go: up one dir, main page]

WO2003039468A3 - Antimnemonic therapy for hypermemory syndromes - Google Patents

Antimnemonic therapy for hypermemory syndromes Download PDF

Info

Publication number
WO2003039468A3
WO2003039468A3 PCT/US2002/035524 US0235524W WO03039468A3 WO 2003039468 A3 WO2003039468 A3 WO 2003039468A3 US 0235524 W US0235524 W US 0235524W WO 03039468 A3 WO03039468 A3 WO 03039468A3
Authority
WO
WIPO (PCT)
Prior art keywords
antimnemonic
therapy
hypermemory
syndromes
disorders
Prior art date
Application number
PCT/US2002/035524
Other languages
French (fr)
Other versions
WO2003039468A2 (en
WO2003039468B1 (en
Inventor
John L Haracz
Original Assignee
John L Haracz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by John L Haracz filed Critical John L Haracz
Priority to AU2002354041A priority Critical patent/AU2002354041A1/en
Priority to CA002465869A priority patent/CA2465869A1/en
Publication of WO2003039468A2 publication Critical patent/WO2003039468A2/en
Publication of WO2003039468A3 publication Critical patent/WO2003039468A3/en
Publication of WO2003039468B1 publication Critical patent/WO2003039468B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to antimnemonic therapy for the treatment of behaviroal disorders such as addiction, obsessive-compulsive disorder, Tourette's Syndrome, post-traumatic stress disorder (PTSD), bipolar disorder, depression, schizophrenia, anxiety disorders and personality disorders. Antimnemonic therapy may involve cue- or psychotherapy-induced reactivation of memories in combination with the administration of antimnemonic drugs.
PCT/US2002/035524 2001-11-06 2002-11-05 Antimnemonic therapy for hypermemory syndromes WO2003039468A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2002354041A AU2002354041A1 (en) 2001-11-06 2002-11-05 Antimnemonic therapy for hypermemory syndromes
CA002465869A CA2465869A1 (en) 2001-11-06 2002-11-05 Antimnemonic therapy for hypermemory syndromes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33271301P 2001-11-06 2001-11-06
US60/332,713 2001-11-06

Publications (3)

Publication Number Publication Date
WO2003039468A2 WO2003039468A2 (en) 2003-05-15
WO2003039468A3 true WO2003039468A3 (en) 2003-10-23
WO2003039468B1 WO2003039468B1 (en) 2003-11-27

Family

ID=23299527

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/035524 WO2003039468A2 (en) 2001-11-06 2002-11-05 Antimnemonic therapy for hypermemory syndromes

Country Status (3)

Country Link
AU (1) AU2002354041A1 (en)
CA (1) CA2465869A1 (en)
WO (1) WO2003039468A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8118722B2 (en) 2003-03-07 2012-02-21 Neuronetics, Inc. Reducing discomfort caused by electrical stimulation
US7153256B2 (en) 2003-03-07 2006-12-26 Neuronetics, Inc. Reducing discomfort caused by electrical stimulation
TW200531680A (en) * 2004-03-03 2005-10-01 Merz Pharma Gmbh & Co Kgaa Therapy using 1-aminocyclohexane derivatives for the treatment of behavioral disorders associated with alzheimer's disease
US7601115B2 (en) 2004-05-24 2009-10-13 Neuronetics, Inc. Seizure therapy method and apparatus
ATE506945T1 (en) * 2004-09-20 2011-05-15 Sinai School Medicine USE OF MEMANTINE (NAMENDA) TO TREAT AUTISM, OCD BEHAVIOR, AND IMPULSIVITY
US7857746B2 (en) 2004-10-29 2010-12-28 Nueronetics, Inc. System and method to reduce discomfort using nerve stimulation
US7396326B2 (en) 2005-05-17 2008-07-08 Neuronetics, Inc. Ferrofluidic cooling and acoustical noise reduction in magnetic stimulators
US7824324B2 (en) 2005-07-27 2010-11-02 Neuronetics, Inc. Magnetic core for medical procedures
WO2008045641A2 (en) * 2006-10-10 2008-04-17 The University Of Chicago Composition s comprising a benzodiazepine, an alcohol aversive agent and an abuse aversive agent
WO2008051610A2 (en) * 2006-10-26 2008-05-02 Mclean Hospital Corporation, The Treatment of impulse control disorders
DK2872145T3 (en) 2012-07-12 2022-06-13 Emalex Biosciences Inc CONDENSED BENZAZE PINS FOR THE TREATMENT OF TOURETE'S SYNDROME
WO2016061320A2 (en) * 2014-10-15 2016-04-21 Rowan University Timber therapy for post-traumatic stress disorder

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5338738A (en) * 1993-04-19 1994-08-16 Bristol-Myers Squibb Company Cerebral function enhancers: acyclic amide derivatives of pyrimidinylpiperidines
US5863934A (en) * 1995-09-21 1999-01-26 Amy F. T. Arnsten Use of lofexidine in the treatment of behavioral disorders
US5962494A (en) * 1991-06-26 1999-10-05 Sepracor Inc. Methods for treating behavioral and other disorders using optically pure R(+) ondansetron

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962494A (en) * 1991-06-26 1999-10-05 Sepracor Inc. Methods for treating behavioral and other disorders using optically pure R(+) ondansetron
US5338738A (en) * 1993-04-19 1994-08-16 Bristol-Myers Squibb Company Cerebral function enhancers: acyclic amide derivatives of pyrimidinylpiperidines
US5863934A (en) * 1995-09-21 1999-01-26 Amy F. T. Arnsten Use of lofexidine in the treatment of behavioral disorders

Also Published As

Publication number Publication date
CA2465869A1 (en) 2003-05-15
AU2002354041A1 (en) 2003-05-19
WO2003039468A2 (en) 2003-05-15
WO2003039468B1 (en) 2003-11-27

Similar Documents

Publication Publication Date Title
IL256054A (en) Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
WO2004014953A3 (en) Anti-myelin associated glycoprotein (mag) antibodies
WO2002002624A3 (en) B7-like molecules and uses thereof
WO2003039468A3 (en) Antimnemonic therapy for hypermemory syndromes
WO2002024891A3 (en) B7-like molecules and uses thereof
WO2004006858A3 (en) Compounds, compositions, and methods employing same
IL163102A (en) Dihydrobenzodiazepin-2-one derivatives, process for their preparation and use thereof in the preparation of medicaments for the treatment of neurological disorders
WO2003060071A3 (en) Albumin fusion proteins
WO2000054813A3 (en) Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
EP1463530A4 (en) Adeno-associated virus-mediated delivery of gdnf to skeletal muscles
WO2002024234A3 (en) Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
WO2004074232A8 (en) 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases
CA2436540A1 (en) Pharmaceutical compositions based on anticholinergics and corticosteroids
DE60214846D1 (en) Use of mGLuR5 antagonists for the manufacture of medicaments for the treatment of sensitive X syndromes, autism and mental retardation
DE60216305D1 (en) COMPOSITIONS FOR THE ADMINISTRATION OF MEDICINAL COMBINATIONS
WO2005116088A3 (en) Methods and compositions for treating diseases and disorders associated with siglec-8 expressing cells
UA82828C2 (en) The use of enantiomeric pure escitalopram for treatment of depression
AU2001266152A1 (en) Novel substituted nitrocatechols, their use in the treatment of some central andperipheral nervous system disorders and pharmaceutical compositions containing them
WO2005009460A3 (en) Pharmaceutical composition comprising activin a, alk-4 or derivatives thereof for the treatment of ophthalmic disorders or cancer
WO2004098536A3 (en) Anti-viral activity of cathelicidin peptides
WO2003025139A3 (en) Cobalamin mediated delivery of nucleic acids, analogs and derivatives thereof
ZA200400313B (en) Use of BIBN4096 in combination with other antimigraine drugs for the treatment of migraine.
HK1063601A1 (en) Compositions and methods for treating hyperimmune response in the eye
WO2005063757A3 (en) Novel crystalline forms of temozolomide
WO2006028492A3 (en) hC1Q/TNF7 AND USES THEREOF

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
B Later publication of amended claims

Free format text: 20030818

WWE Wipo information: entry into national phase

Ref document number: 2465869

Country of ref document: CA

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP